Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-3-23
pubmed:abstractText
To determine the safety and outcome following standard-dose ibritumomab tiuxetan followed by BEAM high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0301-472X
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
534-40
pubmed:meshHeading
pubmed-meshheading:17379063-Adult, pubmed-meshheading:17379063-Aged, pubmed-meshheading:17379063-Antibodies, Monoclonal, pubmed-meshheading:17379063-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17379063-Carmustine, pubmed-meshheading:17379063-Combined Modality Therapy, pubmed-meshheading:17379063-Cytarabine, pubmed-meshheading:17379063-Disease-Free Survival, pubmed-meshheading:17379063-Female, pubmed-meshheading:17379063-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:17379063-Humans, pubmed-meshheading:17379063-Lymphoma, Non-Hodgkin, pubmed-meshheading:17379063-Male, pubmed-meshheading:17379063-Melphalan, pubmed-meshheading:17379063-Middle Aged, pubmed-meshheading:17379063-Podophyllotoxin, pubmed-meshheading:17379063-Salvage Therapy, pubmed-meshheading:17379063-Stem Cell Transplantation, pubmed-meshheading:17379063-Transplantation Conditioning, pubmed-meshheading:17379063-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
pubmed:affiliation
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
pubmed:publicationType
Journal Article, Clinical Trial